JUVÉDERM® VOLUX™ XC

Caution: Federal (USA) law restricts this device to sale by or on the order of a licensed physician or properly licensed practitioner.

BEFORE USING THIS PRODUCT, READ THE FOLLOWING INFORMATION THOROUGHLY.

1. DEVICE DESCRIPTION
JUVÉDERM® VOLUX™ XC injectable gel is a sterile, biodegradable, non-pyrogenic, viscoelastic, clear, colorless, homogeneous gel implant. It consists of hyaluronic acid (HA) produced by Streptococcus species of bacteria crosslinked with BDDE, formulated to a concentration of 25 mg/mL with 0.3% w/w lidocaine in a physiologic buffer.

2. INTENDED USE/INDICATIONS
JUVÉDERM® VOLUX™ XC injectable gel is indicated for subcutaneous and/or suprapriosteal injection for improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition.

3. CONTRAINDICATIONS
- JUVÉDERM® VOLUX™ XC is contraindicated for patients with severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies.
- JUVÉDERM® VOLUX™ XC contains trace amounts of gram-positive bacterial proteins and is contraindicated for patients with a history of allergies to such material.
- JUVÉDERM® VOLUX™ XC contains lidocaine and is contraindicated for patients with a history of allergies to such material.

4. WARNINGS
- The product must not be injected into blood vessels. Introduction of JUVÉDERM® VOLUX™ XC injectable gel into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting the product, for example, after insertion of the needle, and just before injection, the plunger rod can be withdrawn slightly to aspirate and verify the needle is not intravascular, inject the product slowly and apply the least amount of pressure necessary. Rare but serious adverse events (AEs) associated with the intravascular injection of injectable gels in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures. Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and possibly evaluation by an appropriate health care professional specialist should an intravascular injection occur (see HEALTH CARE PROFESSIONAL INSTRUCTIONS #17).
- Product use at specific sites in which an active inflammatory process (skin eruptions such as cysts, pimples, rashes, or hives) or infection is present should be deferred until the underlying process has been controlled.
- Injection site responses (ISRs) consist mainly of short-term inflammatory symptoms and generally resolve within 2 weeks. Refer to the ADVERSE EVENTS section for details.

5. PRECAUTIONS
- JUVÉDERM® VOLUX™ XC injectable gel is packaged for single-patient use. Do not resterilize. Do not use if package is open or damaged.
- In order to minimize the risk of potential complications, this product should only be used by health care professionals who have been trained in facial anatomy and vasculature, safe injection techniques, and identification and management of potential AEs, including intravascular complications.
- Health care professionals are encouraged to discuss all potential risks of soft tissue injections with their patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications.
- Based on preclinical studies and a toxicological risk assessment, patients should be limited to 20 mL of any JUVÉDERM® injectable gel per 60 kg (132 lbs) body mass per year. The safety of injecting greater amounts has not been established.
- This product is intended for improving jawline definition. The safety and effectiveness for the treatment of anatomic regions in other areas of the body have not been established in controlled clinical studies.
- Injection of more than 9 mL of JUVÉDERM® VOLUX™ XC for improvement of jawline definition has not been studied.
- As with all transcutaneous procedures, injections of this product can carry a risk of infection. Standard precautions associated with injectable materials should be followed.
- JUVÉDERM® VOLUX™ XC is to be used as supplied. Modification or use of the product outside the Directions for Use may adversely impact the sterility, homogeneity, and performance of the product.
- The safety for use during pregnancy, in breastfeeding females, and in patients under 22 years has not been established.
- The safety in patients with known susceptibility to keloid formation, hypertrophic scarring, or pigmentation disorders has not been studied.
- JUVÉDERM® VOLUX™ XC should be used with caution in patients on immunosuppressive therapy.
- Patients who are using substances that can prolong bleeding (such as aspirin, nonsteroidal anti-inflammatory drugs, and warfarin) may, as with any injection, experience increased bruising or bleeding at injection sites.
- Patients may experience late onset AEs with use of injectable gel implants, including JUVÉDERM® VOLUX™ XC. Refer to ADVERSE EVENTS section for details.
- After use, treatment syringes and needles are biohazards. Handle and dispose of these items in accordance with accepted medical practice and applicable local, state, and federal requirements.
- JUVÉDERM® VOLUX™ XC injectable gel is a clear, colorless gel without visible particulates. In the event that the content of a syringe shows signs of separation and/or appears cloudy, do not use the syringe; notify Allergan Product Surveillance at 1-877-345-5372.
- JUVÉDERM® VOLUX™ XC should only be used by health care professionals who have appropriate experience and who are knowledgeable about the anatomy and the product for use in the jawline.
- If laser treatment, chemical peel, or any other procedure based on active dermal response is considered after treatment with JUVÉDERM® VOLUX™ XC, there is a possible risk of eliciting an inflammatory reaction at the implant site. An inflammatory reaction is also possible if the product is administered before the skin has healed completely after such a procedure.
- Failure to comply with the needle attachment instructions could result in needle disengagement and/or product leakage at the Luer-Lok® and needle hub connection.

6. ADVERSE EVENTS
A. US Pivotal Study of JUVÉDERM® VOLUX™ XC
In the randomized, controlled, multicenter clinical study to evaluate the safety and effectiveness of JUVÉDERM® VOLUX™ XC for improving jawline definition, 156 participants were randomized to treatment and received injections in the jaw area (pre- and post-jowl sulci, chin, marionette lines, and mandible) during the primary phase of the study. Touch-up treatments occurred approximately 30 days after initial injection, if needed. After the 6-month blinded “no-treatment” control period, control participants were offered treatment; 42 control participants elected to receive treatment. Treatment group participants were offered a maintenance treatment 12 months after the last treatment. A total of 87 treatment group participants opted for the maintenance treatment.
Participants used electronic diaries to record specific signs and symptoms of ISRs,Except for delayed-onset touch-up, and maintenance treatments. Participants were instructed to rate each ISR listed on the diary as Mild, Moderate, Severe, or None.

- Mild ISRs were defined as symptoms causing little, if any, discomfort leading to little, if any, effect on daily activities.
- Moderate ISRs were defined as symptoms causing some discomfort leading to some effect on daily activities.
- Severe ISRs were defined as symptoms causing great discomfort leading to compromised performance of daily activities.

The severity and duration of all ISRs reported by > 5% of participants after initial treatment (from both the treatment and Control groups) are summarized in Table 1. Most ISRs were mild or moderate (75%, 147/196 for Total Treatment-related AEs) after initial interative touch-up lasting (14 or less) days. A total of 35% (69/196) of ISRs lasted between 15 to 30 days. The incidence, severity, and duration of ISRs reported after the touch-up and maintenance treatments were similar to those reported after initial treatment.

### Table 1. ISRs by Severity and Duration After Initial Treatment with JUVÉDERM® VOLUX ™ XC Occurring in > 5% of Treated Participants

<table>
<thead>
<tr>
<th>Severity</th>
<th>Total (198)</th>
<th>Mild (147)</th>
<th>Moderate (16)</th>
<th>Severe (9)</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>198</td>
<td>147</td>
<td>16</td>
<td>9</td>
<td>1-14 Days</td>
</tr>
<tr>
<td>Mild</td>
<td>147</td>
<td>147</td>
<td>0</td>
<td>9</td>
<td>1-14 Days</td>
</tr>
<tr>
<td>Moderate</td>
<td>16</td>
<td>13</td>
<td>2</td>
<td>1</td>
<td>15-30 Days</td>
</tr>
<tr>
<td>Severe</td>
<td>9</td>
<td>0</td>
<td>0</td>
<td>9</td>
<td>&gt;30 Days</td>
</tr>
</tbody>
</table>

The following AEs were received from postmarket surveillance on the use of VOLUX™ XC outside the United States and were not observed in the clinical study: indicates that treatment did not affect facial sensation.

### Table 2. Severity and Duration of Treatment-Related AEs in the Treated Population (JUVÉDERM® VOLUX ™ XC Treated and Maintenance Treatment populations; Treated and maintenance Treatment populations)

<table>
<thead>
<tr>
<th>AEs</th>
<th>Participants (n=198)</th>
<th>Severity</th>
<th>Time to Onset (Days after last treatment)</th>
<th>Duration (Days)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injection site swelling</td>
<td>Mild</td>
<td>84</td>
<td>6</td>
<td>6</td>
<td>Recovered/Resolved</td>
</tr>
<tr>
<td>Injection site swelling</td>
<td>Moderate</td>
<td>29</td>
<td>7</td>
<td>4</td>
<td>Recovered/Resolved</td>
</tr>
<tr>
<td>Injection site nodule</td>
<td>Mild</td>
<td>4</td>
<td>7</td>
<td>7</td>
<td>Recovered/Resolved</td>
</tr>
<tr>
<td>Injection site nodule</td>
<td>Moderate</td>
<td>1</td>
<td>12</td>
<td>12</td>
<td>Recovered/Resolved</td>
</tr>
<tr>
<td>Hypersensitivity reaction</td>
<td>Moderate</td>
<td>17</td>
<td>12</td>
<td>12</td>
<td>Recovered/Resolved</td>
</tr>
<tr>
<td>Muscle twitching</td>
<td>Mild</td>
<td>10</td>
<td>13</td>
<td>13</td>
<td>Recovered/Resolved</td>
</tr>
<tr>
<td>Muscle twitching</td>
<td>Moderate</td>
<td>1</td>
<td>14</td>
<td>14</td>
<td>Recovered/Resolved</td>
</tr>
</tbody>
</table>

### Table 3. Treatment-Related AEs with Duration Greater than 3 Days in the Treated Population (JUVÉDERM® VOLUX ™ XC Treated and Maintenance Treatment populations)

<table>
<thead>
<tr>
<th>AE</th>
<th>Severity</th>
<th>Time to Onset (Days after last treatment)</th>
<th>Duration (Days)</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Injection site swelling</td>
<td>Mild</td>
<td>217</td>
<td>6</td>
<td>Recovered/Resolved</td>
</tr>
<tr>
<td>Injection site nodule</td>
<td>Moderate</td>
<td>70</td>
<td>80</td>
<td>Recovered/Resolved</td>
</tr>
</tbody>
</table>

### Table 4. Treatment-Related AEs with Onset Days Greater than 30 Days After Last Treatment with JUVÉDERM® VOLUX ™ XC Treated Population

- **Study Endpoints**
  - The primary effectiveness measure for the study was the blinded Evaluating Investigator’s photo assessment of the participant’s jawline using the validated Allergan Loss of Jawline Definition Scale (ALJDS). A responder was defined as a participant with ≥ 1-point improvement in Jawline Score compared to baseline.
  - The secondary effectiveness measure was the patient-reported Blinding at Least One Dimension (ALJDS).
  - The following AEs were reported from postmarket surveillance on the use of JUVÉDERM® VOLUX ™ XC outside the United States and were not observed in the clinical study: indicates that treatment did not affect facial sensation.

### Other Safety Assessments

#### Jaw Functional Limitation Scale

- Participants (n=198) who were randomized to the treatment group, 157 participants were randomized to the treatment group and 49 participants were randomized to the delayed-treatment control group. Treatment group participants underwent treatment with JUVÉDERM® VOLUX ™ XC (treatment area is depicted in Figure 1), followed by an optional touch-up treatment 1 month after initial treatment, if deemed necessary to achieve optimal improvement, with follow-up visits at 1, 3, 6, 9, and 12 months after the last treatment. Maintenance treatment was offered to treatment group participants at 12 months after treatment, with follow-up visits 1 and 3 months after treatment. Control group participants attended a follow-up visit at 1, 3, 6, and 9 months during the “no treatment” control period. Thereafter, control participants were offered study treatment and optional touch-up with post-treatment follow-up visits at 1, 3, 6, 9, and 12 months after last treatment.

#### Postmarket Surveillance

- The study included a postmarket surveillance assessment using the Global Aesthetic Improvement Scale (GAIS) and participant satisfaction using the validated Satisfaction with Lower Face and Jawline module of the FACE-Q® questionnaire.

### Participant Demographics

- Participants' demographics and pretreatment characteristics of the treatment and control groups are presented in Table 6.
The Evaluating Investigators rated the majority of treatment group participants (89.0%, 130/146) as showing improvement in overall aesthetic appearance at 6 months based on the GAIS, with the majority continuing to show improvement through 12 months (73.9%, 107/134). At 6 months, 88.4% (129/146) of treatment group participants reported improvement in the overall aesthetic appearance of their jawline area (N = 157). Most treatment group participants continued to report improvement on the GAIS at 12 months (74.3%, 104/140).

Prior to treatment, the patient’s medical history should be obtained, effective patient assessment, safe injection techniques, and complications. Health care practitioners may contact Allergan for educational resources are available through the Allergan Medical Educator, which provides training in facial anatomy and vasculature, and the Allergan Institute, which provides training in facial anatomy and vasculature, the patient’s treatment goals should be characterized by evidence-based recommendations from the American Society for Dermatologic Surgery Task Force and the American Society for Aesthetic Plastic Surgery. Health care practitioners are encouraged to conduct vision assessments, including visual acuity, extracoronal vision testing.

3. Patient’s treatment goals should be characterized by evidence-based recommendations from the American Society for Dermatologic Surgery Task Force and the American Society for Aesthetic Plastic Surgery. Health care practitioners are encouraged to conduct vision assessments, including visual acuity, extracoronal vision testing.

4. Prior to treatment, the patient’s medical history should be obtained, effective patient assessment, safe injection techniques, and complications. Health care practitioners may contact Allergan for educational resources are available through the Allergan Medical Educator, which provides training in facial anatomy and vasculature, and the Allergan Institute, which provides training in facial anatomy and vasculature, the patient’s treatment goals should be characterized by evidence-based recommendations from the American Society for Dermatologic Surgery Task Force and the American Society for Aesthetic Plastic Surgery. Health care practitioners are encouraged to conduct vision assessments, including visual acuity, extracoronal vision testing.

5. The patient’s treatment goals should be characterized by evidence-based recommendations from the American Society for Dermatologic Surgery Task Force and the American Society for Aesthetic Plastic Surgery. Health care practitioners are encouraged to conduct vision assessments, including visual acuity, extracoronal vision testing.

6. Before and after treatment, health care practitioners are encouraged to conduct vision assessments, including visual acuity, extracoronal vision testing.

7. The patient’s treatment goals should be characterized by evidence-based recommendations from the American Society for Dermatologic Surgery Task Force and the American Society for Aesthetic Plastic Surgery. Health care practitioners are encouraged to conduct vision assessments, including visual acuity, extracoronal vision testing.

8. Supplementary anesthesia may be used for additional pain management during and after injection.

9. After ensuring that the patient has thoroughly washed the treatment area with soap and water, the area should be patted with alcohol or other antiseptic. Prior to injecting, depress the plunger rod until the product is dispensed out of the needle. If immediate blanching occurs, the injection should be stopped, and the area should be massaged until it returns to a normal color. Blanching may represent a vessel occlusion. If normal skin coloring does not return, do not continue with the injection. Treat in accordance with American Society for Dermatologic Surgery guidelines, which include hylacons™ XC injectable gel. Hylacons™ XC injectable gel is a highly crosslinked, non-animal based, sterile, preservative-free injectable hyaluronic acid dermal filler product designed for use in facial rejuvenation and contouring applications.

10. When injection is completed, the treated site should be gently massaged so that it conforms to the contour of the surrounding tissue. The effects of the injection should be massaged to blend with the area you are working against the underlying superficial bone to obtain optimal results.
19. With patients who have localized swelling, the degree of effect is sometimes difficult to judge at the time of treatment. In this case, it is better to invite the patient back to the office for a touch-up treatment.

20. After the initial treatment, an additional treatment may be necessary to achieve the desired level of effect. If further treatment is needed, the same procedure should be repeated until a satisfactory result is obtained. The need for an additional treatment may vary from patient to patient and is dependent upon a variety of factors, such as treatment goals, skin elasticity, and dermal thickness at the treatment site.

21. Patients may experience mild to moderate ISRs after treatment, which typically resolve within 2 weeks. Ice using gentle pressure for a brief period following treatment to minimize swelling and reduce pain.

22. The health care professional should instruct the patient to promptly report to her/him regarding any evidence of problems possibly associated with the use of JUVÉDERM VOLUX™ XC.

C. Patient Instructions
It is recommended that the following information be shared with patients:

- Avoid applying makeup for 12 hours after treatment. Within the first 24 hours, patients should avoid strenuous exercise, extensive sun or heat exposure, and alcoholic beverages. Exposure to any of the above may cause temporary redness, swelling, and/or itching at the injection sites.
- To report an adverse reaction, notify Allergan Product Surveillance at 1-877-345-5372.

9. HOW SUPPLIED
JUVÉDERM VOLUX™ XC injectable gel is supplied in individual treatment syringes with 27-G needles for single-patient use and ready for injection (implantation). The TSK STERIGLIDE™ 25-G 1½” cannula is not supplied with JUVÉDERM VOLUX™ XC but is available for purchase through Allergan. The volume in each syringe is as stated on the syringe label and on the carton. The contents of the syringe are sterile and non-pyrogenic. Do not resterilize. Do not use if package is open or damaged.

10. SHELF LIFE AND STORAGE
JUVÉDERM VOLUX™ XC injectable gel should not be used after the expiration date printed on the label.

Store at room temperature (up to 25°C/77°F). DO NOT FREEZE.

JUVÉDERM VOLUX™ XC injectable gel has a clear appearance. In the event that a syringe contains material that is not a clear, colorless gel without visible particulates, do not use the syringe; notify Allergan Product Surveillance immediately at 1-877-345-5372.

To place an order, contact Allergan at 1-800-377-7790.